Preferred Label : VR-CAP Regimen;
NCIt synonyms : Bortezomib/Cyclophosphamide/Doxorubicin/Prednisone/Rituximab; Bortezomib-Cyclophosphamide-Doxorubicin-Prednisone-Rituximab; Bortezomib/Rituximab/Cyclophosphamide/Doxorubicin/Prednisone; Bortezomib/Cyclophosphamide/Doxorubicin/Prednisone/Rituximab Regimen; Bortezomib-Cyclophosphamide-Doxorubicin-Prednisone-Rituximab Regimen; Bortezomib/Cyclophosphamide/Doxorubicin/Prednisone Plus Rituximab; Velcade/Rituxan-Cyclophosphamide/Adriamycin/Prednisone; VR-CAP;
NCIt related terms : VR-CAP (rituximab-abbs); VR-CAP (rituximab-blit); VR-CAP (rituximab-rixi); VR-CAP (rituximab-rite); VR-CAP (rituximab-rixa); VR-CAP (rituximab-arrx); VR-CAP (rituximab-pvvr);
NCIt definition : A regimen consisting of bortezomib, cyclophosphamide, doxorubicin, prednisone and
rituximab that can be used for the treatment of mantle cell lymphoma.;
NCI Metathesaurus CUI : CL1664727;
Codes from synonyms : 24552; 127829; 128457; 127986; 128614; 128771; 128143; 128300;
Origin ID : C181653;
UMLS CUI : C5557198;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
